Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial - 02/11/18
, Toshihiko Doi, MD a, Mikhail Dvorkin, MD b, Wasat Mansoor, MD c, Hendrik-Tobias Arkenau, MD d, Aliaksandr Prokharau, ProfMD e, Maria Alsina, MD f, Michele Ghidini, MD g, Catia Faustino, MD h, Vera Gorbunova, MD i, Edvard Zhavrid, ProfMD j, Kazuhiro Nishikawa, MD k, Ayumu Hosokawa, MD l, Şuayib Yalçın, ProfMD m, Kazumasa Fujitani, MD n, Giordano D Beretta, MD o, Eric Van Cutsem, Prof p, Robert E Winkler, MD q, Lukas Makris, PhD r, David H Ilson, MD s, Josep Tabernero, MD fSummary |
Background |
Trifluridine/tipiracil showed activity and was well tolerated in a phase 2 study of pretreated patients with advanced gastric cancer done in Japan. We investigated whether the treatment was efficacious compared with placebo in a global population.
Methods |
TAGS was a randomised, double-blind, placebo-controlled, phase 3 trial done in 110 academic hospitals in 17 countries. Patients aged 18 years or older with histologically confirmed, non-resectable, metastatic gastric adenocarcinoma (including adenocarcinoma of the gastroesophageal junction) as defined by the American Joint Committee on Cancer staging classification (7th edition) who had received at least two previous chemotherapy regimens and had experienced radiological disease progression were eligible for inclusion. Patients were randomly assigned (2:1) via dynamic randomisation from a centralised interactive voice-response system to receive either oral trifluridine/tipiracil (35 mg/m2 twice daily on days 1–5 and days 8–12 every 28 days) plus best supportive care or placebo plus best supportive care. Participants were allocated to groups by study-site personnel. Randomisation was stratified by region (Japan vs rest of world), ECOG performance status (0 vs 1), and previous treatment with ramucirumab (yes vs no). Both patients and investigators were masked to treatment allocation. The primary endpoint was overall survival. Efficacy was assessed in the intention-to-treat population and safety in all patients who received at least one dose of treatment. This trial is registered with ClinicalTrials.gov, number NCT02500043. The trial, including follow-up of all participants, has been completed.
Findings |
Between Feb 24, 2016, and Jan 5, 2018, 507 patients were enrolled and randomly assigned, 337 to the trifluridine/tipiracil group and 170 to the placebo group. Median overall survival was 5·7 months (95% CI 4·8–6·2) in the trifluridine/tipiracil group and 3·6 months (3·1–4·1) in the placebo group (hazard ratio 0·69 [95% CI 0·56–0·85]; one-sided p=0·00029, two-sided p=0·00058). Grade 3 or worse adverse events of any cause occurred in 267 (80%) patients in the trifluridine/tipiracil group and 97 (58%) in the placebo group. The most frequent grade 3 or worse adverse events of any cause were neutropenia (n=114 [34%]) and anaemia (n=64 [19%]) in the trifluridine/tipiracil group and abdominal pain (n=15 [9%]) and general deterioration of physical health (n=15 [9%]) in the placebo group. Serious adverse events of any cause were reported in 143 (43%) patients in the trifluridine/tipiracil group and 70 (42%) in the placebo group. One treatment-related death was reported in each group (because of cardiopulmonary arrest in the trifluridine/tipiracil group and because of toxic hepatitis in the placebo group).
Interpretation |
Trifluridine/tipiracil significantly improved overall survival compared with placebo and was well tolerated in this heavily pretreated population of patients with advanced gastric cancer. Trifluridine/tipiracil could be a new treatment option in this population who represent a high unmet medical need.
Funding |
Taiho Oncology and Taiho Pharmaceutical.
Le texte complet de cet article est disponible en PDF.Plan
Vol 19 - N° 11
P. 1437-1448 - novembre 2018 Retour au numéro
Article précédent
- Developing cancer care institutions for the developing world – Investigator’s response
- Bhawna Sirohi, C S Pramesh, Shailesh V Shrikhande, Susannah Stanway, Richard Sullivan
- Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study
- Tadeusz Robak, Jie Jin, Halyna Pylypenko, Gregor Verhoef, Noppadol Siritanaratkul, Johannes Drach, Markus Raderer, Jiri Mayer, Juliana Pereira, Gayane Tumyan, Rumiko Okamoto, Susumu Nakahara, Peter Hu, Carlos Appiani, Sepideh Nemat, Franco Cavalli, LYM-3002 investigators, Achiel Van Hoof, Adriana Sheliga, Adriana Teixeira, Akihiro Tomita, Albert Oriol Rocafiguera, Alexander Suvorov, Alexy Kuzmin, Ali Khojasteh, Amel Mezlini, Anatoly Golenkov, Andre Bosly, Andrew Belch, Ann Van De Velde, Árpád Illes, Ashis Mukhopadhyay, Balkis Meddeb, Bernard De Prijck, Bernardo Garichochea, Bulent Undar, Caballero Gabarrón, Carmen Cao, Carmino Souza, Charles Farber, Cheol Won Suh, Cristina Ileana Burcoveanu, Cristina Ligia Cebotaru, Cristina-Ligia Truica, Dai Maruyama, David Belada, Dina Ben Yehuda, Dmitry Udovitsa, Enrica Morra, Ernst Späth-Schwalbe, Eva Gonzalez-Barca, Evgenii Osmanov, Francisco Javier Capote, Fritz Offner, Galvez Cardenas, Georg Heß, Georgii Manikhas, Govind Babu, Grigoriy Rekhtman, Guiseppe Rossi, Herlander Marques, Horia Bumbea, Huaqing Wang, Huiqiang Huang, Ilseung Choi, Irina Bulavina, Irina Lysenko, Irit Avivi, Iryna Kryachok, Jan Maciej Zaucha, Jan Novak, Joaquín Díaz, Judit Demeter, Julia Alexeeva, Jun Zhu, Kateryna Vilchevskaya, Kenichi Ishizawa, Kenny Mauricio, Kensei Tobinai, Kiyoshi Ando, Kudrat Abdulkadryrov, Lee-Yung Shih, Lyudmila Kuzina, Mahmut Gumus, Maike De Wit, Marcelo Capra, Margarida Marques, Marina Golubeva, Mario Ojeda-Uribe, Maryna Kyselyova, Masafumi Taniwaki, Massimo Federico, Michael Crump, Michele Baccarani, Michinori Ogura, Miklós Egyed, Miklos Udvardy, Mitsutoshi Kurosawa, Naokuni Uike, Nuriet Khuageva, Ofer Shpilberg, Oleg Gladkov, Olga Samoilova, Olga Serduk, Patricia Santi, Pierre Zachee, Polina Kaplan, Razvan Stoia, Remy Gressin, Reyes Arranz, Richard Greil, Sebastian Grosicki, Sergio Cancelado, Sreejith Nair, Steven Le Gouill, Steven Van Steenweghen, Sung-Soo Yoon, Suporn Chuncharune, Tatiana Scheider, Tatsu Shimoyama, Ting Liu, Tomohiro Kinoshita, Toshiki Uchida, Udomsak Bunworasate, Umberto Vitolo, Viacheslav Pavlov, Vijay Rao Phooshkooru, Vladimir Lima, Vladimir Merkulov, Weerasak Nawarawong, Xiaonan Hong, Xiaoyan Ke, Yasuhito Terui, Yeow Tee Goh, Yoshiharu Maeda, Yuankai Shi, Yuri Dunaev, Yurii Lorie, Zhao Wang, Zhixiang Shen, Zita Borbenyi, Zoltán Gasztonyi, Zvenyslava Masliak
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?